The pharmacokinetics of nebulized amikacin in the lung and in the blood and its therapeutic effects on VAP due to Gram-negative bacteria

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-12002697

Enrollment

Unknown

Registered

2012-10-11

Start date

2010-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventilator-associated pneumonia

Interventions

control group:routine intravenous antibiotics conbined with nebulized normal saline as placebo

experimental group:routine intravenous antibiotics conbined with nebulized nebulized amikacin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) meeting the diagnostic criteria of VAP and expected to survive at least 7 days; 2) having the normal serum creatinine values; 3) with age between 18 and 85 years old; 4) with Gram-negative bacilli found by sputum spear; 5) written informed consent.

Exclusion criteria

Exclusion criteria: 1) pregnancy; 2) history of allergy to amikicin; 3) use of immunosuppressive agents, and 4) with lung tumours.

Design outcomes

Primary

Measure	Time frame
mortality;weaning rate;	—

Secondary

Measure	Time frame
clinical pulmonary infection score;white blood cell count;temperature;oxgenation index;procalcitonin;C-reactive protein;	—

Countries

China

Contacts

Public ContactTang Jiangguo

tangjianguo@5thhospital.com+86 18918168576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026